ORGO (Organogenesis Holdings Inc. Class A Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by ORGO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-24 | Brian Grow | Chief Commercial Officer | M | — | — |
| 2026-03-11 | Arthur S Leibowitz | Director | Buy | — | — |
| 2026-03-11 | Michael Joseph Driscoll | Director | Buy | — | — |
| 2026-03-03 | Robert Cavorsi | Vice President, Strategy | F | — | — |
| 2026-03-03 | Antonio S. Montecalvo | Vice President, Health Policy | MIXED | — | — |
| 2026-03-03 | Robert Cavorsi | Vice President, Strategy | MIXED | — | — |
| 2026-03-03 | Gary S. Gillheeney | President and CEO | MIXED | — | — |
| 2026-03-03 | Brian Grow | Chief Commercial Officer | MIXED | — | — |
| 2026-03-03 | Patrick Bilbo | Chief Operating Officer | MIXED | — | — |
| 2026-03-03 | Lori Freedman | Chief Admin. and Legal Officer | MIXED | — | — |
| 2026-03-03 | David Francisco | Chief Financial Officer | MIXED | — | — |
| 2026-02-20 | Michele Ilene Korfin | Director | A | — | — |
| 2026-02-20 | Patrick Bilbo | Chief Operating Officer | MIXED | — | — |
| 2026-02-20 | Antonio S. Montecalvo | Vice President, Health Policy | MIXED | — | — |
| 2026-02-20 | Garrett Lustig | Director | A | — | — |
| 2026-02-20 | Jon L Giacomin | Director | A | — | — |
| 2026-02-20 | Brian Grow | Chief Commercial Officer | MIXED | — | — |
| 2026-02-20 | Michael Joseph Driscoll | Director | A | — | — |
| 2026-02-20 | Prathyusha Duraibabu | Director | A | — | — |
| 2026-02-20 | Gilberto Quintero | Director | A | — | — |
| 2026-02-20 | Gary S. Gillheeney | President and CEO | MIXED | — | — |
| 2026-02-20 | Lori Freedman | Chief Admin. and Legal Officer | MIXED | — | — |
| 2026-02-20 | Robert Cavorsi | Vice President, Strategy | MIXED | — | — |
| 2026-02-20 | Arthur S Leibowitz | Director | A | — | — |
| 2026-02-20 | David Francisco | Chief Financial Officer | MIXED | — | — |
| 2026-02-18 | Gary S. Gillheeney | President and CEO | F | — | — |
| 2026-02-18 | Brian Grow | Chief Commercial Officer | F | — | — |
| 2026-02-18 | Lori Freedman | Chief Admin. and Legal Officer | F | — | — |
| 2026-02-18 | Patrick Bilbo | Chief Operating Officer | F | — | — |
| 2026-02-18 | David Francisco | Chief Financial Officer | F | — | — |
| 2026-02-18 | Robert Cavorsi | Vice President, Strategy | F | — | — |
| 2026-02-18 | Antonio S. Montecalvo | Vice President, Health Policy | F | — | — |
| 2025-12-18 | GLENN H NUSSDORF | Director | Sell | — | — |
| 2025-11-26 | GLENN H NUSSDORF | Director | Sell | — | — |
| 2025-11-03 | GLENN H NUSSDORF | Director | MIXED | — | — |
| 2025-08-13 | Brian Grow | Chief Commercial Officer | MIXED | — | — |
| 2025-07-18 | Robert Cavorsi | Vice President, Strategy | F | — | — |
| 2025-06-06 | Lori Freedman | Chief Admin. and Legal Officer | Buy | — | — |
| 2025-03-12 | Robert Cavorsi | Vice President, Strategy | F | — | — |
| 2025-03-06 | Michael Joseph Driscoll | Director | Sell | — | — |
| 2025-03-04 | Robert Cavorsi | Vice President, Strategy | F | — | — |
| 2025-02-21 | Jon L Giacomin | Director | A | — | — |
| 2025-02-21 | Garrett Lustig | Director | A | — | — |
| 2025-02-21 | Lori Freedman | Chief Admin. and Legal Officer | A | — | — |
| 2025-02-21 | Prathyusha Duraibabu | Director | A | — | — |
| 2025-02-21 | Arthur S Leibowitz | Director | A | — | — |
| 2025-02-21 | David Francisco | Chief Financial Officer | A | — | — |
| 2025-02-21 | Michael Joseph Driscoll | Director | A | — | — |
| 2025-02-21 | Gilberto Quintero | Director | A | — | — |
| 2025-02-21 | Brian Grow | Chief Commercial Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 118,896,054 | — |
| — | 10%+ Owner | 118,455,161 | — |
| — | 10%+ Owner | 111,033,430 | — |
| — | 10%+ Owner | 110,533,430 | — |
| — | 10%+ Owner | 102,170,806 | — |
| — | 10%+ Owner | 102,170,806 | — |
| — | Director | 102,170,804 | — |
| — | 10%+ Owner | 102,170,804 | — |
| — | 10%+ Owner | 61,989,237 | — |
| — | 10%+ Owner | 59,448,027 | — |
| — | 10%+ Owner | 59,277,696 | — |
| — | 10%+ Owner | 54,136,225 | — |
| — | 10%+ Owner | 51,085,403 | — |
| — | Director | 29,840,171 | — |
| — | Director | 25,517,514 | — |
| — | Director | 18,975,165 | — |
| — | Director | 16,999,665 | — |
| — | Director | 7,721,298 | — |
| — | President and CEO | 4,232,087 | — |
| — | Director | 2,901,310 | — |
| — | Chief Operating Officer | 1,144,687 | — |
| — | Chief Admin. and Legal Officer | 1,038,054 | — |
| — | Chief Commercial Officer | 900,682 | — |
| — | Chief Financial Officer | 731,312 | — |
| — | Director | 291,014 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ORGO quote page; the site-wide leaderboard is on the insider transactions hub.